Related by context. All words. (Click for frequent words.) 70 Sprague Dawley rats 69 male Sprague Dawley 68 Wistar rats 65 μmol L 64 MBq 63 ovariectomized 63 Genotypes 63 multiple logistic regression 63 intraperitoneal injection 63 umol L 62 serum leptin 61 mg Pycnogenol 61 C#BL 6 mice 61 differentially expressed genes 61 % CI #.#-#.# [003] 61 microgram kg 61 deoxy 61 underwent surgical resection 61 hepatoma 60 mononuclear 60 saline placebo 60 rFSH 60 μg kg 60 metabolite concentrations 60 nutlin 3a 60 flutamide 60 microg 60 sitosterol 60 baseline LDH 60 cynomolgus monkeys 60 bronchoalveolar lavage BAL 60 tertiles 60 nmol 60 db db mice 60 allele frequencies 60 thyrotropin 60 serum concentrations 60 adjunctive placebo 60 Baseline characteristics 60 papillary renal cell carcinoma 59 mutated K ras 59 ICSI cycles 59 retrospective cohort 59 differential gene expression 59 nontreated 59 CC genotype 59 supernatants 59 inbred strains 59 immunohistochemical staining 59 Apidra ® 59 LEXIVA r 59 mol L 59 isotypes 59 Sterilization Supplies Markets Independently 59 ABCB1 59 thyroglobulin 59 dimensional echocardiography 59 heterozygotes 59 Insulin sensitivity 59 homozygotes 59 prostate carcinoma 59 pairwise comparisons 59 syngeneic 59 somatization disorder 59 mCi m 2 59 mg eq 59 prospectively randomized 59 nondiabetic patients 59 #Gy 58 dosing cohorts 58 -#.# ± [002] 58 abacavir lamivudine 58 femoral shaft fracture 58 folate vitamin B 58 Tumor Response 58 hyperlipidemic 58 doxorubicin cyclophosphamide 58 immunostaining 58 MTT assay 58 mCi 58 Excretion 58 hypercholesterolemic 58 euthyroid 58 unfractionated heparin UFH 58 confidence intervals CIs 58 Secretase 58 triiodothyronine 58 histological subtype 58 logistic regression analysis 58 dose proportionality 58 #mg/kg [002] 58 underwent CABG 58 cisplatin resistant 58 T2DM 58 hyperinsulinemic euglycemic clamp 58 Mg Uk 58 uM 58 adjunctive ABILIFY 58 vitamin D3 supplements 58 multivariate analyzes 58 Dosages 58 H#K#me# 58 C#BL 6 58 μl 58 PREZISTA ritonavir 58 isoprostane 58 ug mL 58 ethyl ester 58 Supplementary Table 58 logistic regression 58 hamartomas 58 serologically 58 fasting plasma 58 adiponectin concentrations 58 mean ± SEM 58 μg ml 58 missense mutations 58 ANOVA 58 hepatocellular carcinomas 58 Decitabine 58 REYATAZ r arm 58 ileal 58 hydroxylase 58 Liver biopsies 58 Lymphocyte 58 randomized controlled trials RCTs 58 System IPSS 58 #S rRNA 58 intraperitoneally 58 Subtypes 58 metaplasia 58 lymphocytosis 58 genes differentially expressed 58 SDS PAGE 58 factorial design 58 n = 58 DAS# scores 57 ascending dose 57 posttreatment 57 nucleotide substitutions 57 amoxicillin clavulanate 57 K ras mutations 57 ug kg 57 alanine aminotransferase ALT 57 glucose insulin 57 β blockers 57 mcg albinterferon alfa 2b 57 4mg/kg 57 bronchoalveolar lavage 57 conditional logistic regression 57 semiquantitative 57 metabolic parameters 57 efavirenz EFV 57 daunorubicin 57 subscale scores 57 relapsed MM 57 apolipoproteins 57 intraabdominal 57 Index CDAI 57 MIC# [001] 57 Experimentally 57 pyridostigmine 57 unfractionated 57 saline injections 57 factorial 57 calcaneal fractures 57 spinous 57 univariate 57 bone marrow stromal cells 57 μg L 57 CD3 + 57 daily subcutaneous injections 57 Chronic HCV 57 N acetyl 57 iobenguane 57 mononuclear cells 57 oxycodone IR 57 multicenter randomized controlled 57 budesonide pMDI 57 BMI ≥ 57 triacylglycerol 57 GlcNAc 57 ertapenem 57 logistic regression analyzes 57 HBeAg positive 57 underwent resection 57 K#N 57 REYATAZ ritonavir 57 Cholinesterase Inhibitors 57 logistic regression model 57 HMGA1 57 lactis 57 GnRH agonist 57 microsatellite markers 57 pyrimidines 57 seropositivity 56 pharmacokinetic parameters 56 colorectal adenoma 56 kDa protein 56 generalized estimating 56 SCIg 56 prospective randomized multicenter 56 folic acid vitamin B6 56 apolipoprotein B 56 glulisine 56 pharmacodynamic parameters 56 homozygote 56 Amino acid 56 TIMP 1 56 antithymocyte globulin 56 micrograms mcg 56 immunoglobulin G 56 interquartile range 56 anthropometric measurements 56 monocytic 56 zoledronate 56 leukocyte count 56 extramedullary 56 intramuscularly 56 bacterial isolates 56 umbilical vein 56 -#.# log# 56 5alpha reductase 56 5 hydroxytryptamine 56 atazanavir ritonavir 56 mg kg dose 56 flavopiridol 56 Primary endpoints 56 cyclophosphamide methotrexate 56 histologically 56 monosaccharide 56 C#Y 56 multivariate Cox 56 #mg QD [002] 56 #mg/day [001] 56 MADRS score 56 FASEB J. 56 electrophysiologic 56 aspartate aminotransferase AST 56 Cytotoxicity 56 coexpression 56 Progenitor Cells 56 #mg q8h 56 timepoints 56 equimolar 56 pmol liter 56 FDG PET scans 56 neutrophil counts 56 #:#-# [029] 56 nelfinavir 56 mcg BID 56 Estrogen Receptor 56 Autograft 56 diuretic chlorthalidone 56 cellularity 56 C#BL/#J 56 EGFP 56 NHANES III 56 lanthanum carbonate 56 nondiabetic 56 HepG2 cells 56 % CI #.#-#.# [008] 56 coding genes 56 HLA DR4 56 GSTP1 56 METHODS 56 Poisson regression 56 cervical lymph nodes 56 postmenopausal osteoporotic women 56 NPH insulin 56 Intervention Trial 56 biochemical relapse 56 genotypic resistance 56 seronegative 56 unconjugated 56 histologic subtype 56 cranial irradiation 56 mm Hg diastolic 56 plus medroxyprogesterone acetate 56 Western blotting 56 poor metabolizers 56 conjugated equine estrogen 56 intra articular injection 56 mature oocytes 56 Serum concentrations 56 lysates 56 UGT#A# * 56 mcg ml 56 Meta analyzes 56 titrated glipizide 56 prospectively stratified 56 HCV SPRINT 56 hours postdose 56 Prospective Randomized Trial 56 cefazolin 56 mg simvastatin 56 beta. 56 nucleated cells 56 biopsy specimens 56 IGFBP 3 56 aspartate aminotransferase 56 pyrimidine 56 HT 1A 56 fig. S2 56 hematopoietic cancers 56 lopinavir r arm 56 IFN g 56 Multivariate analysis 56 breast carcinomas 56 bivariate 56 cDNA libraries 56 mU liter 56 tertile 56 pharmacologically active isomer 56 ritonavir boosted 56 IGFBP 56 cefotaxime 56 fasting triglyceride levels 56 mmol 56 atypical neuroleptics 56 Polymorphism 56 E. faecalis 56 cynomolgus macaques 56 renal tumors 56 Differentially 56 histologically confirmed 56 mg/m2 dose 56 seminomas 56 Fig. 3b 56 differentially regulated 56 Gravimetric finish 56 ECOG PS 56 immunohistochemical 56 Inflammatory Pain 56 SGOT 56 intraobserver 56 multivariable analysis 56 randomized crossover 56 THIS STUDY 55 HBeAg negative 55 ethambutol 55 trials RCTs 55 physiologic parameters 55 pigtail macaques 55 mCi kg 55 ovariectomized rats 55 Ischemic 55 siRNA knockdown 55 μg g 55 cells uL 55 mesalamine granules 55 circadian genes 55 remifentanil 55 EURIDIS 55 chest radiographs 55 Alanine 55 homogenates 55 quetiapine risperidone 55 vastus lateralis 55 FLT3 ITD 55 PFGE 55 covariate 55 prospective observational cohort 55 subfamilies 55 induced sputum 55 PFOS PFOA 55 bronchoalveolar lavage fluid 55 mRNA expression 55 ß carotene 55 fraternal twin pairs 55 overt hypothyroidism 55 PBMCs 55 Subgroup analysis 55 microalbumin 55 CD4 CD8 55 histologically proven 55 paricalcitol 55 Histopathological 55 SGPT 55 apo AI 55 keto 55 Histologic 55 null mice 55 severe NCI Grades 55 nonpregnant women 55 immunohistochemical analysis 55 plasma pharmacokinetics 55 Haplotype 55 infliximab monotherapy 55 Brief Psychiatric 55 nulliparous women 55 randomized multicenter trial 55 coding exons 55 ascending doses 55 Pearson correlation coefficient 55 genotype 1a 55 ^ Tc 55 ANCOVA 55 Genotypic 55 weekly subcutaneous injections 55 μg mL 55 comparator arm 55 preintervention 55 dosage regimens 55 #mg/day [002] 55 underwent radical prostatectomy 55 RFLP 55 immunofluorescence microscopy 55 lactulose 55 immunoblotting 55 dimensional ultrasonography 55 glucuronide 55 ß blockers 55 Tubulin 55 BRAF V#E 55 postintervention 55 liver transplant recipients 55 receptor blocker 55 pmol L 55 glutamyl 55 metastatic lymph nodes 55 nonpsychotic 55 #mg/kg [001] 55 IFN α 55 Multicenter Randomized 55 maternal serum 55 Figure 2C 55 Lymphocytes 55 F FDG PET 55 efficacy evaluable 55 HIV uninfected 55 mg BID dose 55 piperacillin tazobactam 55 dimensional sonography 55 TMC# r 55 tacrolimus ointment 55 Non Responders 55 mg d 55 BoNT 55 MRSA isolates 55 NMIBC 55 NSCLC tumors 55 mg RDEA# 55 mEq 55 PREZISTA r arm 55 fig. S1 55 conjugated estrogens 55 mcg mL 55 isocaloric 55 PaO 2 55 EGFR HER2 55 darunavir ritonavir 55 F FDG 55 Immunomodulatory 55 blind randomized controlled 55 ,#,# [002] 55 lispro 55 q#h 55 pleiotropic effects 55 bolus dose 55 Immune Responses 55 CD# + [001] 55 lipid lowering agents 55 cilostazol 55 HLA A2 55 bivariate analyzes 55 PEG IFN 55 IFN alfa 55 JAK2 V#F 55 griseofulvin 55 mg q#h 55 indels 55 VNTR 55 mcg doses 55 active comparator 55 cDNA microarray 55 lung adenocarcinomas 55 #:# randomization 55 methotrexate monotherapy 55 multivariate logistic regression 55 Corynebacterium 55 BEXXAR Therapeutic Regimen 55 hydroxyphenyl 55 dehydrogenases 55 sulfadiazine 55 CsA 55 interferon alfa 2b 55 phosphate dehydrogenase 55 exendin 4 55 LRTI 55 ALT elevation 55 blinded placebo controlled 55 intact parathyroid hormone 55 Kidney Int 55 Bifidobacterium 55 stepwise logistic regression 55 proband 55 clinico pathological 55 serum homocysteine 55 papillomas 55 tocopherol 55 hemoglobin Hb 55 pmol 55 placebo capsules 55 ERalpha 55 Bifidobacterium lactis 55 Secondary efficacy endpoints 55 PUFA intake 55 ml min 55 hyperplastic 55 pT3 55 adriamycin 55 octreotide LAR 55 Kruskal Wallis test 54 MMSE scores 54 chemoradiation therapy 54 genotyped 54 FDG uptake 54 DRD2 54 cDNAs 54 Placebo controlled 54 ^ sup #m 54 Intensity Modulated 54 transfected 54 direct thrombin inhibitors 54 monozygotic twins 54 Cytotoxic 54 phylogenetically 54 dyads 54 psychiatric outpatients 54 CAMMS# 54 transaminase elevations 54 paralogs 54 #mmHg [001] 54 NIHSS 54 serum testosterone 54 Nutrition EPIC 54 endometrial thickness 54 interrater reliability 54 -#.# ± [001] 54 Genetic Variation 54 Transcriptome 54 Randomized Controlled Trials 54 % Confidence Interval 54 PCR RFLP 54 Am J Cardiol 54 esophageal reflux 54 monophosphate 54 ligand receptor 54 log# copies mL 54 HCV genotypes 54 metastatic GIST 54 serum IgG 54 Peginterferon Alfa 2a 54 HLA DR 54 Apolipoprotein 54 LH RH 54 cGy 54 galiximab 54 irbesartan 54 #ß 54 MMSE score 54 peroxidase 54 telomere lengths 54 mg administered orally 54 tipranavir ritonavir 54 monocyte chemotactic protein 54 % CI #.#-#.# [007] 54 subthreshold 54 Epoetin Alfa 54 intergenic regions 54 MetS 54 Omacetaxine mepesuccinate 54 Clinical Relevance 54 Randomized Study 54 fluoxetine paroxetine 54 glycoprotein IIb IIIa inhibitors 54 alkaline phosphatase ALP 54 tumor xenograft models 54 EQ 5D 54 odds ratios ORs 54 Neonates 54 NOD mice 54 Eur Urol 54 eosinophil count 54 CK # administered 54 congenital toxoplasmosis 54 colorectal adenocarcinoma 54 Peginterferon 54 Scale PANSS 54 hypophosphatemia 54 Prostaglandin 54 aspirin clopidogrel 54 melanocytic nevi 54 stoichiometry 54 COL#A# 54 serum IGF 54 CTL epitopes 54 univariate analyzes 54 Phenotypic 54 MATERIALS AND METHODS 54 Stent Restenosis 54 #μg [001] 54 Sentinel Lymph Node 54 pyrantel pamoate 54 Cyclophosphamide 54 ara C 54 ALT flares 54 Free Full Text 54 interleukin IL -6 54 stavudine d4T 54 metabolizing enzymes 54 rs# [001] 54 TEAEs 54 HIV HCV coinfected 54 immunocompetent 54 intravenous bolus 54 κ 54 underwent liver transplantation 54 Cytogenetic 54 overnight polysomnography 54 GSTM1 54 #.#mg/kg [002] 54 Immunoglobulin 54 GHRH 54 statistical significance p 54 Nucleotide 54 elevated ALT 54 J Am Soc 54 hematological parameters 54 prospective nonrandomized 54 mutant allele 54 undetectable HBV DNA 54 mRNA transcripts 54 mL kg 54 Prostatic 54 mg TID 54 UKPDS 54 genetic loci 54 X Chromosome 54 Teriflunomide 54 p = #.# [003] 54 lung metastases 54 mIU ml 54 pimecrolimus cream 54 point Likert scale 54 antiretroviral naïve 54 TRAIL R1 54 activating mutation 54 clomipramine 54 logistic regression models 54 primary hypercholesterolemia 54 clinicopathological 54 antiepileptics 54 Pharmacokinetics PK 54 benzimidazole 54 nonmetastatic 54 genotypic 54 kcal d 54 invasive carcinomas 54 Complication rates 54 IQR 54 Autoantibodies 54 cytochromes 54 Cystectomy 54 HSCT 54 gibbon ape 54 ROC curves 54 Adrenergic 54 ALT elevations 54 prospectively enrolled 54 β1 54 cytochrome 54 clinicopathologic 54 prucalopride 54 TT genotype 54 liver biopsies 54 International Prognostic Scoring 54 #-#,# mg 54 NOAEL 54 platelet dysfunction 54 leukocyte counts 54 r2 = 54 antral 54 morphometric 54 serum estradiol 54 plasma glucose concentration 54 pg mL 54 CORE OM 54 BPS IC 54 Liraglutide Effect 54 hexose 54 raphe 54 -#.# log# copies mL 54 RQ PCR 54 treatment naïve genotype 54 Incontinence Impact Questionnaire 54 Adenoviral 54 telaprevir dosed 54 carboxyl terminal 54 HGPIN 54 microarray experiments 54 PSA nadir 54 HCV replicon 54 intramedullary nailing 54 undergone radical prostatectomy 54 Placebo Controlled Study 54 mg FV 54 hemagglutination inhibition 54 lymphadenectomy 54 collagenous colitis 54 lactate dehydrogenase 54 TNFalpha 54 cirrhotic 54 tolterodine ER 54 nadolol 54 serum albumin 54 fibrosarcoma 54 Pooled Analysis 54 Human Leukocyte Antigen 53 hydroxymethyl 53 RRM1 53 aspartate 53 PDGFR alpha 53 5HT 53 experimental allergic encephalomyelitis 53 C#BL/#J mice 53 Pegylated Liposomal Doxorubicin 53 operable breast cancer 53 FDG PET imaging 53 pulvinar 53 Follicular Lymphoma 53 intravesical instillation 53 cells μL 53 GISSI 53 aminotransferase levels 53 zonisamide SR 53 orthologous 53 Oral Fingolimod 53 outbred 53 isoforms 53 creatinine ratio 53 Patient Populations 53 hypothalamic pituitary 53 lysate 53 osteosarcomas 53 surgically resected 53 DAPT 53 % CI #.#-#.# [004] 53 HER2 expression 53 EMRG VIO 53 nadroparin 53 Kahalalide F 53 SSRI SNRI 53 Posaconazole 53 J Nutr 53 hepatic resection 53 syndromal 53 WHIMS 53 homodimer 53 somatostatin 53 Fig. 1D 53 mcg linaclotide 53 suppl. 53 tetramer 53 Histological 53 evaluable subjects 53 NNRTI resistance 53 Angiotensin Converting Enzyme 53 ug dose 53 nonobese 53 biologic DMARD 53 Nat Genet 53 nephrectomy 53 interleukin IL 53 Wilcoxon rank sum 53 insulin detemir 53 PON1 activity 53 caspofungin 53 antibody titer 53 J Natl Cancer Inst 53 KRAS mutations 53 hemodialysis patients 53 μg dose 53 gene expression microarrays 53 observational cohort 53 Leydig cell 53 GH deficiency 53 R#W [002] 53 recurrent glioblastoma multiforme 53 NSABP B 53 QD dosing 53 rt PA 53 haplotypes 53 isoenzyme 53 replicase 53 confidence interval #.#-#.# 53 antiandrogens 53 methoxy 53 IIIa inhibitors 53 double blinded placebo 53 ergot alkaloids 53 Cancer Res 53 treatment emergent AEs 53 macrolide antibiotic 53 lopinavir r 53 somatoform disorders 53 Solid Tumors 53 acyl CoA 53 covariance 53 Abdominal Fat 53 PCa 53 Polyp Prevention Trial 53 serum lipids 53 plantarum 53 Cardiotoxicity 53 μg d 53 ml kg 53 #S rRNA genes 53 peripheral blood mononuclear 53 Bonferroni correction 53 binary logistic regression 53 mU L 53 dioxygenase 53 affective psychosis 53 reverse transcriptase inhibitors 53 baseline FEV 53 Allogeneic 53 mg/m2/day 53 Hematopoietic 53 plasmacytoid 53 DOI #.#/S#-# 53 kg -1 53 adefovir treated 53 #S #S [003] 53 cytidine 53 triglyceride TG 53 cytokeratin 53 serum TSH 53 ABCB1 gene 53 Haplogroup 53 sulfonamide 53 capsular polysaccharide 53 subcutaneous dose 53 benzothiazole 53 IgG4 53 acupoints 53 Arch Intern Med 53 bronchial responsiveness 53 Endometrial 53 treatment naive genotype 53 Peg IFN 53 Soft Tissue Sarcoma 53 glucose intolerant 53 subsamples 53 enzyme immunoassay EIA 53 LPV r 53 methylation patterns 53 μg liter 53 fasting triglycerides 53 orthologs 53 glucosamine hydrochloride 53 ug ml 53 transcriptomic 53 mL/min/#.# m2 53 Randomised 53 Double Blind Randomized 53 serum antibodies 53 amisulpride 53 multivariable Cox 53 Infarct 53 HOMA IR 53 nonobese patients 53 distinct subtypes 53 plasmid encoding 53 Multivariate logistic regression 53 venlafaxine XR 53 K#R [002] 53 Brain Metastases 53 #.#-#.# [011] 53 #ug [002] 53 #p# [003] 53 Randomized Clinical Trial 53 urodynamic 53 rFVIIa 53 multicenter randomized placebo controlled 53 prospective multicentre 53 Engerix B 53 cytologically confirmed 53 interrater 53 Au ICP# 53 placebo controlled studies 53 GLUT1 53 rHuEPO 53 orthotopic 53 Hurthle cell 53 #S rRNA gene 53 meropenem 53 AST ALT 53 normotensive 53 partial remissions 53 placebo PBO 53 interobserver 53 ejection fractions 53 cold pressor test 53 isoenzymes 53 immunoconjugate 53 C#T [002] 53 glycolytic 53 Confocal microscopy 53 Descriptive statistics 53 oral allopurinol 53 eplerenone 53 p ≤ 53 FAME Study 53 Salmonella spp 53 microbiologically evaluable 53 lysine residues 53 logistic regressions 53 fasting insulin 53 gametocytes 53 mcg QD 53 mechanically ventilated 53 M#V 53 randomized blinded 53 postop 53 cross sectionally 53 PREZISTA rtv 53 Inflammatory Markers 53 NSTE ACS 53 sonographically 53 randomized multicenter 53 variance ANOVA 53 pancreatic adenocarcinoma 53 categorical variables 53 seroconverted 53 ceftazidime 53 external beam radiotherapy 53 transduced 53 arthroplasties 53 #mg BID [003] 53 oocyst 53 intravitreal injections 53 oral hypoglycemic 53 Juvenile Idiopathic Arthritis 53 Supplemental Figure 53 low dose cytarabine 53 normal karyotype 53 Antitumor 53 Prospective Cohort Study 53 nondemented 53 pramlintide metreleptin combination 53 clodronate 53 J Virol 53 human chorionic gonadotropin hCG 53 pleural fluid 53 mmol l 53 BALF 53 rizatriptan 53 highest tertile 53 ± SEM 53 chronic HCV genotype 53 Signaling Pathway 53 INVEGA ® 53 isoproterenol 53 receiving VICTRELIS 53 Transesophageal 53 metabolomic profiles 53 prostate cancer PCa 53 MDRD 53 ± SD 53 alanine aminotransferase 53 c Fos 53 CDAI 53 mild renal insufficiency 53 pg ml 53 EDSS score 53 Leucovorin 53 Fig. 2A 53 BENICAR HCT 53 Efficacy endpoints 53 FABP 53 multicentre randomized 53 intradermal injections 53 radical nephrectomy 53 C1q 53 angiopoietin 53 μM 53 HIF 1a 53 prospectively evaluated 53 ANCA associated 53 splenic 53 prostaglandin E 53 FUS protein 53 Immunosuppression 53 Rab5 53 uricase 53 Univariate 52 J Pediatr